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Correspondence Highly Sensitive Noninvasive Cardiac
Transplant Rejection Monitoring Using
Targeted Quantiﬁcation of Donor-Speciﬁc
Cell-Free Deoxyribonucleic AcidTo the Editor: Approximately 20,000 cardiac transplant recipients
currently reside in the United States. Rejection remains a
major cause of graft failure and requires lifelong surveillance.
The current gold standard for monitoring rejection is catheter-
based endomyocardial biopsy (EMB), which is associated with
risk and expense (1). Donor-speciﬁc cell-free deoxyribonucleic acid
(DScf-DNA) has been proposed as a marker for cellular injury
caused by rejection (2). Shotgun whole-genome sequencing (WGS)
has been used to detect DScf-DNA (3). The complexity and cost of
the analysis required by WGS limits its application as a surveillance
tool. We have employed targeted quantitative genotyping to
determine the %DScf-DNA. The targeted approach relies on
selected highly-informative genomic regions and potentially pro-
vides a rapid (24 to 48 h) cost-efﬁcient (signiﬁcantly less than
whole genome sequencing) method suitable for clinical surveillance.
We applied this method to detect DScf-DNA in pediatric cardiac
transplant recipients in a prospective blinded study.
Cardiac transplant recipients followed at the Herma Heart
Center at the Children’s Hospital of Wisconsin were invited to
participate. Blood samples (5 ml) were collected in 3 clinical
scenarios:
1. Scheduled surveillance EMB from asymptomatic heart
transplant recipients in the catheterization laboratory
immediately before scheduled surveillance EMB.
2. Unscheduled diagnostic EMB from symptomatic heart
transplant recipients before unscheduled diagnostic EMB.
3. Rejection from heart transplant recipients with biopsy-
proven rejection (> The International Society for Heart and
Lung Transplantation grade 2R or antibody mediated
rejection 1) before initiation of treatment, during treatment,
and at 1 week.
Clinical, laboratory, cardiac catheterization, and echocardio-
graphic data were recorded. Anticoagulated blood was collected
to measure cell-free deoxyribonucleic acid (cf-DNA) levels.
Plasma separation, cf-DNA extraction, and quantiﬁcation of total
cf-DNA were carried out as previously described (4). Genomic
DNA for genotyping was prepared from 1 buffy coat of each
recipient, and donor DNA was obtained from the Blood Center of
Wisconsin. Determination of the %DScf-DNA in recipient plasma
was performed using Digital Analysis of Selected Regions
(DANSR, Ariosa Diagnostics, San Jose, California) (5). Genotyp-
ing of donor and recipient genomic DNA was carried out by the
same assay. Loci are informative when recipient genotypes are ho-
mozygous and donor genotypes are either heterozygous or homo-
zygous for the other allele. The minor allele frequency for
informative loci was modeled as a binomial distribution. The %
DScf-DNA was deﬁned as the peak from this modeling. Summarystatistics included median and range. Unpaired samples (i.e.,
rejection group vs. surveillance group) were compared using a
Mann-Whitney U test. Rejection samples were compared with a
Friedman analysis of variance. A Pearson correlation summarized
correlations. A p value <0.05 was considered signiﬁcant.
Fifty-three samples from 32 patients were analyzed.undergoing 38 scheduled surveillance EMBs (Fig. 1A). Thirty-
Scenario 1. The cf-DNA levels were obtained from 26 patients
two (84%) samples contained <1% DScf-DNA. No patient
with DScf-DNA <1% had pathological rejection. DScf-DNA
levels exceeded 1% in 6 samples, and the highest percentage of
DScf-DNA was associated with asymptomatic biopsy-proven
rejection. The remaining 5 samples had negative biopsies.
Scenario 2. Seven samples were obtained from 6 patients
before unscheduled diagnostic EMB to rule out rejection based on
clinical criteria (Figs. 1B and 1D). Six samples had DScf-DNA
levels >1%, and 1 sample contained DScf-DNA <1%. Four of
the 6 were associated with biopsy-proven rejection; the other 2
patients had signiﬁcant coronary artery vasculopathy on angiog-
raphy. The single symptomatic patient with a low percentage of
DScf-DNA had high levels of total cf-DNA (Fig. 1D), implying
that the dominant pathology was global rather than conﬁned to
the donor organ. This patient was diagnosed with culture-positive
sepsis, the accompanying EMB was negative for rejection, and
coronary angiography was normal.
Scenario 3. Four patients with biopsy-proven rejection were
analyzed. All pre-treatment samples collected at diagnosis con-
tained DScf-DNA >1% (sensitivity 100%). Following intravenous
immunosuppressive therapy, all patients demonstrated signiﬁ-
cantly decreased %DScf-DNA. Interestingly, 3 to 4 days after
discontinuing augmented immunosuppression, the %DScf-DNA
rebounded in 3 of 4 patients (Fig. 1C). The DScf-DNA was
compared with other candidate noninvasive laboratory variables
(B-natriuretic peptide, troponin, and C-reactive protein) as well as
echocardiographically determined left ventricular ejection fraction
in predicting rejection on biopsy; DScf-DNA had the highest
sensitivity and speciﬁcity (100% and 84%, respectively).
DScf-DNA may be sufﬁciently sensitive to detect rejection and
injury to the donor organ earlier than currently available methods.
Levels of DScf-DNA fall consistently by 1 week post-transplant,
which may allow for noninvasive detection of rejection in the
vulnerable early post-transplant period (data not shown). A sensi-
tive noninvasive rejection monitoring method could decrease the
number of biopsies needed over a lifespan, thereby considerably
decreasing complications, discomfort, and cost. We were able to
detect all rejection episodes, including both cellular and antibody-
mediated rejection, at the earliest onset and even before clinical
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Figure 1 cf-DNA in Patients Undergoing Surveillance EMB and During Rejection
Percent donor-speciﬁc cell-free deoxyribonucleic acid (DScf-DNA) in scheduled surveillance endomyocardial biopsy (EMB) (A) and unscheduled diagnostic EMB samples (B).
(C) Boxplot of surveillance EMB samples (black circles) and rejection samples (red circles) collected at 3 time points. (D)Total cell-free deoxyribonucleic acid (cf-DNA) in
unscheduled diagnostic EMB samples. Data in A, B, and D are sorted on the x-axis according to increasing %DScf-DNA. Samples in B and D align vertically. The dashed line in A,
B, and C highlights the 1% DScf-DNA level. The vertical solid line in A orients the picture so that all samples containing <1% DScf-DNA are on the left-hand side and all samples
>1% are on the right. IV ¼ intravenous.
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1225indicators of disease. However, these results are based on a limited
sample size. A larger validation study is needed.
In summary, targeted quantitative genotyping was employed
to determine circulating levels of DScf-DNA in pediatric heart
transplant recipients. The percentage of DScf-DNA was elevated in
all patients diagnosed with rejection. Further, all patients withDScf-
DNA levels <1% were shown by biopsy and clinical parameters to
be negative for rejection (negative predictive value 100%). Targeted
quantitative genotyping of circulating DScf-DNA constitutes a
sensitive, rapid, and cost-effective noninvasive tool potentially
suitable for rejection surveillance as an alternative to EMB.Mats Hidestrand, PhD
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2012;32:3–9.Letters to the EditorTriggering of
Cardiac Arrhythmias
The Problem of Multicollinearity
Among Air Pollution and
Meteorological Factors
Link et al. (1) recently suggested the inﬂuence of ambient air
pollutants on the occurrence of atrial ﬁbrillation, with a 26% in-
crease in the risk of arrhythmic incidence for each 6-mg/m3 increase
in particulate matter <2.5 mg (PM2.5) aerodynamic diameter.
Arguably, the association of acute cardiac events with environ-
mental inﬂuences may not be as simple because of strong correla-
tions between the atmospheric constituents, which may also act as
triggers of cardiac arrhythmias. For example, meteorological factors
correlate with each other, but also substantially inﬂuence
the concentration of air pollutants (2–8). A growing body of evi-
dence has suggested a strong relationship of suspended particulate
matter to wind speed, air pressure and temperature, and relative
humidity (2–5). The problem of multicollinearity may be particu-
larly important for the relationship between meteorological factors
and ambient PM2.5 (3), the particles that showed a signiﬁcant
association with the occurrence of atrial ﬁbrillation in the study by
Link et al. (1).
Link et al. (1) made adjustments for air temperature and dew
point for 24-h periods, which could partly be the reason for
nonsigniﬁcant associations between atrial ﬁbrillation and air pollu-
tion in this analysis. Two previous studies from Poland investigated
the association of the incidence of atrial ﬁbrillation also using daily
meteorological data, but without adjustments. The ﬁrst study has
suggested that meteorological factors such as temperature, relative
humidity, and atmospheric pressure are implicated in the occurrence
of atrial ﬁbrillation in 87% of patients (9). The second study failed
to conﬁrm the inﬂuence of individual meteorological factors, but
found an increased incidence of atrial ﬁbrillation associated with the
passage of a cold front and an occlusion of the cold front type (10).The most important advantage of the study by Link et al. (1) is
the 2-h time window of exposure measurements. However, using
comparable time windows (i.e., 2- and 3-h periods), we reported
that all 4 meteorological factors mentioned above may be involved
in the triggering of both ventricular (11,12) and supraventricular
arrhythmias (13,14), independently of other external triggering
factors including physical activity and emotional stress. High ab-
solute levels of atmospheric pressure and increasing air moisture
were strong predictors of supraventricular tachycardia in all patient
subgroups, as well as both wind speed and blowing of southeasterly
and southwesterly wind directions in male patients (13). Increasing
air moisture was also a strong common predictor of single supra-
ventricular premature beats, whereas atmospheric temperature
correlated with ectopy in participants younger than 65 years of age
(14). In addition, we reported independent associations of atmo-
spheric temperature and pressure, increasing relative air moisture,
and wind speed and direction with the occurrence of ventricular
tachyarrhythmia (11,12).
Possible mechanisms of the inﬂuence of wind speed and direc-
tion on cardiac arrhythmias, such as wind-induced turbulence
and rapid atmospheric pressure oscillations (11–13,15), are highly
speculative. Adverse effects of higher temperatures or increasing
relative air moisture may burden and disturb the human homeo-
stasis, particularly thermoregulatory, hemorheological, cardiovas-
cular, and nervous systems (11,12,16). Higher absolute levels
or decreasing atmospheric pressure have been associated with
enhanced sympathetic activity (12,17,18). In considering their close
inter-relations (2–5), one might expect that such meteorological
conditions cause a more marked endogenous response and trig-
gering burden than air pollution itself.
The main limitation of the research on environmental triggers is
the lack of an adequate methodology. Link et al. (1) used a case-
crossover design, comparing the risk of an incident during expo-
sure and during control periods using conditional logistic regression
(19,20). Although each patient serves as his or her own control, this
design cannot control for meteorological variables and multiple
correlations among environmental factors. To account for the
possibility of multiple environmental triggers of cardiac arrhythmias
(11–14), we applied a framework of multiple regression analysis
with multiple successive measurements for each patient. We sug-
gested that these 2 designs may be considered complementary (11).
However, a more precise estimation of triggering and interaction
effects of environmental factors may only be addressed through
individual patient-based meta-analyses of large-scale data on air
pollution and meteorological factors.
The acute effects of short-term exposure to higher pollution
probably increase the myocardial vulnerability in some patients,
but some concerns about the causal relationship with atrial ﬁbril-
lation and other cardiac arrhythmias remain. There is a scenario in
which increased air pollution is not the only or the direct culprit.
Instead of a single trigger, a cluster of adverse atmospheric con-
ditions may cause an arrhythmic incident. Further studies on in-
teractions among all atmospheric triggers could further our
understanding of the mechanisms of cardiovascular risk associated
with certain atmospheric factors.*Viktor Culic, MD, PhD
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